What is Charles River?
Operating at the intersection of basic research and commercial manufacturing, Charles River provides an integrated suite of services designed to accelerate the development lifecycle. The company serves as a vital partner for organizations navigating the transition from laboratory discovery to clinical application. By offering comprehensive safety assessment, regulatory advisory, and global research capacity, Charles River mitigates the inherent risks associated with bringing new therapeutic agents and medical technologies to market. Its market position is defined by an end-to-end service model that supports clients through every phase of the product development continuum, ensuring both speed and scientific rigor.
How much funding has Charles River raised?
Charles River has raised a total of $258M across 2 funding rounds:
Stock Offering
$224M
Unspecified
$34M
Stock Issuance/Offering (2000): $224M, investors not publicly disclosed
Unspecified (2011): $34M led by National Institutes of Health
Key Investors in Charles River
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing critical support for scientific advancement.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Charles River?
Following this major enterprise-level funding, Charles River is well-positioned to further scale its global operational footprint and enhance its technological capabilities in drug discovery. The strategic allocation of this capital will likely focus on expanding its integrated research platforms and strengthening its regulatory advisory services to meet the evolving needs of the global healthcare sector. As the industry faces increasing pressure to reduce time-to-market for life-saving treatments, Charles River's focus on operational efficiency and scientific excellence will remain the primary driver of its long-term growth trajectory and competitive advantage in the life sciences market.
See full Charles River company page
